According to the study, people suffering from ischemic stroke should exercise caution while opting for stem cell therapy of any kind until more controlled studies come to the fore.
The study financed by the Department of Biotechnology, Ministry of Science and Technology, was conducted over a period of six years between 2008 and 2014 and had sample size of 120 patients, all of whom had suffered from stroke.
Of the 120 patients, 60 patients were assigned to receive conventional treatment and the rest were assigned to bone marrow stem cells treatment besides the conventional treatment.
On an average 28 crore bone marrow cells were injected of which blood forming stem cells were on average 29 lakhs per patient. Later, the patients faced difficulties in using arms and legs.
They were assesed at an interval of 3, 6 months and 12 months and the difficulties they experienced doing various activities of daily livings were measured using two scales which revealed that stem cell treatment is safe but there is no added benefits over the conventional treatment method.
Infact, any patient suffering from disabling and incurable diseases, should not go for stem cell treatment without knowing the scientific effects of it. The new paradigm of clinical practice which is called evidence based medicine requires evidence of clear benefit which outways any risk before a treatment is used in clinical practice," said Kameshwar Prasad, Professor and Head, Department of Neurology & Director of Clinical Epidemiology Unit, AIIMS.
The study, which is the first and largest report on stem cells treatment for stroke has been published in the American Journal "Stroke".
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
